

MEDICINES CO /DE
Form 8-K
February 16, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 9, 2010
The Medicines Company**

(Exact Name of Registrant as Specified in Charter)

Delaware

000-31191

04-3324394

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

**8 Sylvan Way
Parsippany, New Jersey**

07054

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: **(973) 290-6000**

Not applicable.

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On February 9, 2010, the Compensation Committee of the Board of Directors of The Medicines Company (the Company) established the following 2010 base salaries, effective as of January 1, 2010, for the Company s named executive officers, and awarded the following annual cash bonus payments to the Company s named executive officers for 2009 performance, which will be paid in February 2010.

Name and Title	2010 Annual Base Salary	2009 Annual Cash Bonus Payments
Clive A. Meanwell <i>Chief Executive Officer and President</i>	\$ 702,000	\$ 441,480
Glenn P. Sblendorio <i>Executive Vice President and Chief Financial Officer</i>	\$ 486,675	\$ 207,710
Paul M. Antinori <i>Senior Vice President and General Counsel</i>	\$ 392,585	\$ 117,151

The rationale and benchmarking for the named executive officers 2010 base salaries and the method of calculation of the 2009 cash bonus payments will be discussed in the Company s Proxy Statement to be filed in connection with its 2010 Annual Meeting of Stockholders.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE MEDICINES COMPANY

Date: February 16, 2010

By: /s/ Paul M. Antinori

Name: Paul M. Antinori

Title: Senior Vice President and General
Counsel